A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid TumorsScot Ebbinghaus, Lisa A. Hammond, Antti Jekunen et al.|Clinical Cancer Research|2005Cited by 49
Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumorsPeter L. Bonate, L. A. Hammond, Scot Ebbinghaus et al.|Journal of Clinical Oncology|2004Cited by 2
Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumorsPeter L. Bonate, L. A. Hammond, A R Craig et al.|Journal of Clinical Oncology|2004Cited by 0